Mark Beards | Non Executive Director
Sutura Therapeutics

Mark Beards, Non Executive Director, Sutura Therapeutics

Mark Beards is a non-executive director of the company and has over 28 years’ experience in the life sciences and financial sectors within both global organisations and early stage companies. Mark is Chief Executive Officer at Utility Therapeutics He has previously held the role of Corporate Development Director, then Group Chief Financial Officer and Executive Board Member, of Celixir plc, a clinical stage biotechnology company focused on developing cellular regenerative therapies.

He brings a detailed understanding of the life sciences industry from his time at Abbott Laboratories (sales & marketing) and GlaxoSmithKline (R&D) This is augmented by his time at McKinsey & Company as a management consultant focused on supporting senior pharmaceutical clients. He has held a number of senior roles in organisations such as Goldman Sachs (Vice President and Head of European Healthcare Equity Research), Charles River Associates (VP, Life Science Strategy), and KPMG (Director, Life Science Strategy)
Mark holds a BA (Hons) and MA in Mathematics from The Queen’s College, Oxford.

Appearances:



Conference Day 2 - Wednesday 1st April 2020 @ 15:10

Delivering Antisense Oligonucleotides for Rare Disease: Overcoming Translational Hurdles to Enhance Systemic Cargo Delivery.

  • Antisense oligonucleotides approaches can be adapted to a wide range of human disease.
  • Effective delivery strategies of antisense oligonucleotides is urgently required.
  • Sutura are progressing novel approaches to systemic delivery of antisense oligonucleotides for rare disease.
last published: 04/Jun/20 08:25 GMT

back to speakers